Meeting
2018 ASCO Annual Meeting
Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.
Authors
Erica L. Mayer
Dana-Farber Cancer Institute, Waban, MA
Erica L. Mayer , Seth Andrew Wander , Meredith M. Regan , Angela DeMichele , Andres Forero-Torres , Mothaffar F. Rimawi , Cynthia X. Ma , Massimo Cristofanilli , Carey K. Anders , Cynthia Huang Bartlett , Eric P. Winer , Harold J. Burstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS1104)
DOI
10.1200/JCO.2018.36.15_suppl.TPS1104
Abstract #
TPS1104
Poster Bd #
183a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.
First Author: Lorenzo Gerratana
First Author: Cristina I. Truica
Poster
2017 ASCO Annual Meeting
A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.
First Author: Kevin Kalinsky
Poster
2023 ASCO Annual Meeting
Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).
First Author: Alicia Frances Clare Okines